

Tackle Massive MTM Program Expansion with Key Actions for Success

UNDERSTANDING THE CHANGES

The CMS overhaul of the medication therapy management (MTM) program eligibility criteria will usher in major changes for Medicare Part D plans.

With the finalized changes from CMS, the measure* has been moved to display for the 2025-2026 measurement years (possibly returning in MY 2027 for the 2029 Stars). However, CMS still requires annual MTM data submission to maintain Part D contracts.

In addition, plans should get started right away understanding program changes and implementing a strategy to scale up for the influx of newly eligible members.

*Medication Therapy Management (MTM) Program Completion Rate for Comprehensive Medication Review (CMR) measure





CMS has revised the cost threshold to be set at the average cost of 8 generic drugs (from \$5,330 in 2024 to just \$1,623 for 2025).


EXPANDED QUALIFICATIONS WILL INCREASE THE COST OF PROGRAM DELIVERY





CMS acknowledges these changes will lead to additional MA plan costs for approximately \$192 million annually for required MTM services.

THE QUALIFYING LIST OF **CORE CHRONIC CONDITIONS TO ENROLL IN MTM HAS EXPANDED**



CMS is requiring plans to include all 10 core chronic conditions as part of the qualifying criteria. Expanding to 10 from a minimum of 5 in prior years will dramatically increase the list of MTM-eligible members.

THE VOLUME OF ELIGIBLE BENEFICIARIES.

EXPANDED QUALIFICATIONS WILL INCREASE


"We estimate that these changes would increase the number and percentage of Part D enrollees eligible for MTM services from 3.6 million (7%) to 7.1 million (13%)."

Centers for Medicare & Medicaid Services

Chronic Conditions Included in MTM Eligibility

- Alzheimer's Disease
- Bone Disease / Arthritis
- Congestive Heart Failure Diabetes
- Dyslipidemia
- **End-Stage Renal Disease**
- Hypertension Mental Health
- **Respiratory Disease**
- **HIV/AIDS**

FINANCIAL IMPACT



OPTIMIZED MEDICATION UTILIZATION REPRESENTS A

OPPORTUNITY TO REDUCE HEALTHCARE SPENDING

even a small fraction of which would certainly more than compensate plans for the funding required to address the MTM program changes.

Overall, optimized medication utilization represents a

\$500 billion opportunity to reduce healthcare spending,

TOP CAPABILITIES FOR SUCCESS



Plans must be able to accurately identify eligible members, get maximum DTP resolution from

CMRs, and monitor program effectiveness.



Plans must be prepared for rapid scalability.



Plans must find a way to fund the added outreach to the additional members.

Flexible Program **Empowered Clinician**

ADDRESSING PROPOSED CHALLENGES

WITH THE RIGHT MTM CAPABILITIES




Omnichannel program options for growing enrollment and CMR capacity Choice of partner-deployed clinicians

Management

of staffing retention Maintain member experience

for high-quality services without worry

- throughout program growth
- **Robust Data Utilization**



Ultimate CMR effectiveness through maximum drug therapy problem (DTP) identification

Outreach


motivational interviewing to uncover additional adherence gaps Simplified clinician experience

Personal connection through

- through intelligent clinical workflow and easy-to-use interface
- **New Funding Sources**

Alignment of medical and pharmacy data

to maximize DTP identification, adherence



drug swaps

- Identification of specialty drug and site-of-care alternatives Identification of potential formulary-based

Maximized DTP gap closure helps MA plans support the best possible member health outcomes, avoid future medical

spending and maximize future cost savings.

READY TO GET STARTED?

as part of an AdhereHealth MTM solution to prepare

Learn more about the unrivaled capabilities available





for CMS MTM changes.



This can help fund (in whole or in part) MTM program expansion.